Skip to Main Content

Paper Details

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
Cancer Chemother Pharmacol
0
2023
Author NameAffiliation
Min GaoDepartment of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center
Shubham PantUniversity of Texas MD Anderson Cancer Center
Funda Meric-BernstamDepartment of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center
Funda Meric-BernstamUniversity of Texas, MD Anderson Cancer Center
Funda Meric-BernstamThe Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center
  • 1 - 5

Datasets

Release 1.2